{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:08:55Z","timestamp":1778854135309,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.omtm.2023.03.012","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T02:14:28Z","timestamp":1679624068000},"page":"227-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["AAV-mediated expression of HLA-G for the prevention of experimental ocular graft vs. host disease"],"prefix":"10.1016","volume":"29","author":[{"given":"Jacob P.","family":"Nilles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darby","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacklyn H.","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liujiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carly","family":"O\u2019Dea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay T.","family":"Marjoram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacquelyn J.","family":"Bower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew L.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7771-9166","authenticated-orcid":false,"given":"Brian C.","family":"Gilger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2023.03.012_bib1","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/ICO.0b013e3181ca321c","article-title":"Ocular graft-versus-host disease after allogeneic stem cell transplantation","volume":"29","author":"Westeneng","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.omtm.2023.03.012_bib2","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41409-018-0340-0","article-title":"Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the late effects and quality of life working committee of the CIBMTR and transplant complications working party of the EBMT","volume":"54","author":"Inamoto","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omtm.2023.03.012_bib3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/ICU.0b013e32833eab64","article-title":"Current insights into ocular graft-versus-host disease","volume":"21","author":"Riemens","year":"2010","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.omtm.2023.03.012_bib4","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1182\/blood-2011-03-344390","article-title":"Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria","volume":"118","author":"Arai","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2023.03.012_bib5","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1167\/iovs.02-0699","article-title":"Periductal area as the primary site for T-cell activation in lacrimal gland chronic graft-versus-host disease","volume":"44","author":"Ogawa","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2023.03.012_bib6","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/01.icu.0000233952.09595.d8","article-title":"Update on ocular graft versus host disease","volume":"17","author":"Kim","year":"2006","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.omtm.2023.03.012_bib7","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3324\/haematol.2016.149294","article-title":"A prospective randomized trial comparing cyclosporine\/methotrexate and tacrolimus\/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation","volume":"101","author":"T\u00f6rl\u00e9n","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.omtm.2023.03.012_bib8","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1038\/srep03419","article-title":"International chronic ocular graft-vs-host-disease (GVHD) consensus group: proposed diagnostic criteria for chronic GVHD (Part I)","volume":"3","author":"Ogawa","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2023.03.012_bib9","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.ophtha.2016.02.044","article-title":"A clinical trial comparing the safety and efficacy of topical tacrolimus versus methylprednisolone in ocular graft-versus-host disease","volume":"123","author":"Abud","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtm.2023.03.012_bib10","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1097\/ICO.0b013e3181e456f0","article-title":"Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%.","volume":"29","author":"Malta","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.omtm.2023.03.012_bib11","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.bbmt.2012.05.016","article-title":"Clinical benefit of response in chronic graft-versus-host disease","volume":"18","author":"Inamoto","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omtm.2023.03.012_bib12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1096\/fj.04-2078rev","article-title":"HLA-G and immune tolerance in pregnancy","volume":"19","author":"Hunt","year":"2005","journal-title":"Faseb. J."},{"key":"10.1016\/j.omtm.2023.03.012_bib13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1634\/stemcells.2007-0554","article-title":"Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+ CD25highFOXP3+ regulatory T\u00a0cells","volume":"26","author":"Selmani","year":"2008","journal-title":"Stem Cell."},{"key":"10.1016\/j.omtm.2023.03.012_bib14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.humimm.2003.08.346","article-title":"Expression of HLA-G in human cornea, an immune-privileged tissue","volume":"64","author":"Le Discorde","year":"2003","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.omtm.2023.03.012_bib15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1365-2370.1999.00145.x","article-title":"HLA-G and classical HLA class I transcripts in various components of the adult human eye: HLA transcripts in the human eye","volume":"26","author":"Robert","year":"1999","journal-title":"Eur. J. Immunogenet."},{"key":"10.1016\/j.omtm.2023.03.012_bib16","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.humimm.2017.04.007","article-title":"Expression and differential regulation of HLA-G isoforms in the retinal pigment epithelial cell line, ARPE-19","volume":"78","author":"Svendsen","year":"2017","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.omtm.2023.03.012_bib17","doi-asserted-by":"crossref","first-page":"17840","DOI":"10.1038\/s41598-017-18002-9","article-title":"AAV vector-meditated expression of HLA-G reduces injury-induced corneal vascularization, immune cell infiltration, and fibrosis","volume":"7","author":"Hirsch","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2023.03.012_bib18","doi-asserted-by":"crossref","first-page":"19864","DOI":"10.1038\/s41598-019-56462-3","article-title":"AAV-mediated expression of HLA-G1\/5 reduces severity of experimental autoimmune uveitis","volume":"9","author":"Crabtree","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2023.03.012_bib19","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.3390\/ijms23073465","article-title":"Therapeutic applications of adeno-associated virus (AAV) gene transfer of HLA-G in the eye","volume":"23","author":"Gilger","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2023.03.012_bib20","first-page":"3317","article-title":"AAV vector-mediated HLA-G expression to prevent corneal transplant rejection","volume":"59","author":"Gilger","year":"2018","journal-title":"InInvestigative Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2023.03.012_bib21","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.4049\/jimmunol.174.5.3051","article-title":"Alloreactive memory T\u00a0cells are responsible for the persistence of graft-versus-host disease","volume":"174","author":"Zhang","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtm.2023.03.012_bib22","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1167\/iovs.19-27843","article-title":"Graft versus host disease-associated dry eye: role of ocular surface mucins and the effect of rebamipide, a mucin secretagogue","volume":"60","author":"Shamloo","year":"2019","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2023.03.012_bib23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.exer.2016.11.004","article-title":"Assessment of dry eye in a GVHD murine model: approximation through tear osmolarity measurement","volume":"154","author":"Mart\u00ednez-Carrasco","year":"2017","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.omtm.2023.03.012_bib24","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.bbmt.2016.07.012","article-title":"Novel scoring criteria for the evaluation of ocular graft-versus-host disease in a preclinical allogeneic hematopoietic stem cell transplantation animal model","volume":"22","author":"Perez","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omtm.2023.03.012_bib25","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood.V88.8.3230.bloodjournal8883230","article-title":"An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin","volume":"88","author":"Cooke","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2023.03.012_bib26","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1097\/00007890-199006000-00032","article-title":"Diagnosis of graft-versus-host disease in mice transplanted across minor histocompatibility barriers","volume":"49","author":"FONTAINE","year":"1990","journal-title":"Transplantation"},{"key":"10.1016\/j.omtm.2023.03.012_bib27","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.bbmt.2019.08.001","article-title":"Modeling chronic graft-versus-host disease in MHC-matched mouse strains: genetics, graft composition, and tissue targets","volume":"25","author":"M\u00fcller","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omtm.2023.03.012_bib28","doi-asserted-by":"crossref","first-page":"10778","DOI":"10.1096\/fj.201900218R","article-title":"Senescence-associated secretory phenotype promotes chronic ocular graft-vs-host disease in mice and humans","volume":"34","author":"Yamane","year":"2020","journal-title":"Faseb. J."},{"key":"10.1016\/j.omtm.2023.03.012_bib29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.survophthal.2012.08.004","article-title":"Ocular graft-versus-host disease: a review","volume":"58","author":"Shikari","year":"2013","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.omtm.2023.03.012_bib30","first-page":"75","article-title":"Pathogenesis and management of graft-versus-host disease","volume":"30","author":"Choi","year":"2010","journal-title":"Immunol. Allergy Clin."},{"key":"10.1016\/j.omtm.2023.03.012_bib31","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1097\/ICO.0b013e3181e456f0","article-title":"Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05","volume":"29","author":"Malta","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.omtm.2023.03.012_bib32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41434-018-0035-6","article-title":"Serotype survey of AAV gene delivery via subconjunctival injection in mice","volume":"25","author":"Song","year":"2018","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2023.03.012_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/bs.ai.2015.04.001","article-title":"HLA-G: an immune checkpoint molecule","volume":"127","author":"Carosella","year":"2015","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.omtm.2023.03.012_bib34","series-title":"Advances in Immunology","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/bs.ai.2015.04.001","article-title":"HLA-G","author":"Carosella","year":"2015"},{"key":"10.1016\/j.omtm.2023.03.012_bib35","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1182\/blood-2005-12-019919","article-title":"Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by","volume":"108","author":"Fons","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2023.03.012_bib36","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/mi.2010.26","article-title":"Autoimmunity at the ocular surface: pathogenesis and regulation","volume":"3","author":"Stern","year":"2010","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.omtm.2023.03.012_bib37","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.2147\/OPTH.S231804","article-title":"Voretigene neparvovec in retinal diseases: a review of the current clinical evidence","volume":"14","author":"Gao","year":"2020","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.omtm.2023.03.012_bib38","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ymthe.2020.04.004","article-title":"Intrastromal gene therapy prevents and reverses advanced corneal clouding in a canine model of mucopolysaccharidosis I","volume":"28","author":"Miyadera","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.03.012_bib39","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/ICO.0000000000000340","article-title":"Onset of ocular graft-versus-host disease symptoms after allogeneic hematopoietic stem cell transplantation","volume":"34","author":"Shikari","year":"2015","journal-title":"Cornea"},{"key":"10.1016\/j.omtm.2023.03.012_bib40","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s13346-020-00843-z","article-title":"Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives","volume":"11","author":"Gaballa","year":"2021","journal-title":"Drug Deliv. Transl. Res."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123000487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123000487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T13:37:57Z","timestamp":1715953077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050123000487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":40,"alternative-id":["S2329050123000487"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2023.03.012","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV-mediated expression of HLA-G for the prevention of experimental ocular graft vs. host disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2023.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}]}}